Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

Hepatology Research

Volumn 42, Issue 3, 2012, Pages 264-272

  Arase, Yasuji ^a,b   Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kawamura, Yusuke ^a   Akuta, Norio ^a   Imai, Norihiro ^a   Kobayashi, Masahiro ^a   Sezaki, Hitomi ^a   Matsumoto, Naoki ^a   Saito, Satoshi ^a   Hosaka, Tetsuya ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a   Ohmoto, Yuki ^a   Amakawa, Kazuhisa ^a   Hsieh, Shiun Dong ^a   Ogawa, Kyoko ^a   Tanabe, Maho ^a   Tsuji, Hiroshi ^a   Kobayashi, Tetsuro ^b   more..

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Carcinogenesis; Hepatitis C virus; Non alcoholic fatty liver disease

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CHRONIC LIVER DISEASE; COLON CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RANK SUM TEST; RETROSPECTIVE STUDY; SEX; STOMACH CANCER;

EID: 84863126563     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00915.x     Document Type: Article

References (35)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. Williams R. Global changes in liver disease. Hepatology 2006; 44: 521-6.
3. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-98.
4. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
5. Fan JC, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-10.
6. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-18.
7. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007; 46: 716-22.
8. van der Poorten D, Milner KL, Hui J etal. Visceral fat a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.
9. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
10. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54: 333-9.
11. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39: 909-14.
12. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 2008; 133: 92-9.
13. Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 2009; 44: 1064-70.
14. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 (Suppl 1): 63-9.
15. Simonetti RG, Camma C, Fiorello F etal. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case control study. Ann Intern Med 1992; 116: 97-102.
16. Kasahara A, Hayashi N, Mochizuki K etal. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 2: 1394-402.
17. Imai Y, Kawata S, Tamura S etal. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-9.
18. Okanoue T, Itoh Y, Minami M etal. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 653-9.
19. Ikeda K, Saitoh S, Arase Y etal. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C; A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
20. Yasuda K. Early gastric cancer: diagnosis, treatment techniques and outcomes. Eur J Gastroenterol Hepatol 2006; 18: 839-45.
21. Van Gossum A. Guidelines for colorectal cancer screening - a puzzle of tests and strategies. Acta Clin Belg 2010; 65: 433-6.
22. Tsukada K, Takada T, Miyazaki M etal. Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008; 15: 31-40.
23. Cascinu S, Falconi M, Valentini V, S J, Guidelines ESMO. Working Group. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v55-8.
24. Currie GP, Kennedy AM, Denison AR. Tools used in the diagnosis and staging of lung cancer: what's old and what's new? QJM 2009; 102: 443-8.
25. Maresh EL, Mah V, Alavi M etal. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer 2010; 10: 680-7.
26. Harris NL, Jaffe ES, Stein H etal. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
27. Genuth S, Alberti KG, Bennett P etal. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
28. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997; 29: 351-6.
29. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biomedaica 1983; 62: 205-9.
30. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
31. DR Cox. Regression models and life tables. J R Stat Soc 1972; 34: 248-75.
32. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T. The Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2011; 41: 139-47.
33. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-78.
34. Kawamura Y, Ikeda K, Arase Y etal. Viralimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007; 120: 1034-41.
35. Ikeda K, Saitoh S, Suzuki Y etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.